Bausch + Lomb announced it has appointed Brent Saunders as its new CEO and chair of the Board of Directors.
Where do I know him from?
Saunders first served as Bausch + Lomb’s CEO from 2010-2013 and, more recently, was Allergan’s CEO until AbbVie purchased the company in 2020.
What about his predecessor?
The company announced in July 2022 that Joseph C. Papa—CEO of Bausch Health and later Bausch + Lomb since 2016—was stepping down as chairman in July 2022 and that a search for a new CEO had commenced.
Tell me more about Saunders.
He is a 25-year veteran pharma executive and has served in varying leadership roles at global pharmaceutical and healthcare companies such as Schering-Plough Corporation, Forest Laboratories, Actavis, and The Beauty Health Company.
Give me the big picture.
With Bausch + Lomb’s new status as a publicly traded company, Saunders’ industry experience will enable the company to continue focusing on completing its full separation from Bausch Health.
What’s in the company’s pipeline?
See here for an updated list.
When is the transition effective?
Per Bausch + Lomb, Saunders will join the company in an advisory position on February 16, 2023, and officially start as CEO and chair of the Board on March 6, 2023.